aluates Reports

$ 0.0

Automative

Global Biologics and Biosimilars CXO Services Market Research Report 2024

Published Date: November 2024

Report Code: QYRE-Auto-20R18648

BUY CHAPTERS

Global Biologics and Biosimilars CXO Services Market Research Report 2024

Code: QYRE-Auto-20R18648

Report

November 2024

Pages:130

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Companies

Catalent

Thermo Fisher Scientific

Lonza

Siegfried

Recipharm

Boehringer Ingelheim

WuXi AppTech

Wuxi Biologics

Fareva

Samsung Biologics

Aenova

Delpharm

Strides Pharma

Piramal

Famar

Curia

Jubilant

Vetter

AGC Pharma Chemicals

Asymchem

Pharmaron

Eurofins

Ascendia Pharmaceuticals

Ardena

CPL

UPM Pharmaceuticals

FUJIFILM Diosynth Biotechnologies

Groupe Parima

TBD Pharmatech

Avid Bioservices

NextPharma

Alcami

Societal CDMO

MedPharm Ltd.

EUROAPI

BioVectra

Pfizer CentreOne

Fermion

Biologics and Biosimilars CXO Services Market Size

The global Biologics and Biosimilars CXO Services market was valued at US$ 54540 million in 2023 and is anticipated to reach US$ 96550 million by 2030, witnessing a CAGR of 8.5% during the forecast period 2024-2030.

Biologics and Biosimilars CXO Services Market

Biologics and Biosimilars CXO services have gained significant importance as the complexity of biologics and biosimilars development continues to grow. By outsourcing specialized tasks such as clinical trials, process development, and large-scale biologic manufacturing, biopharmaceutical companies can focus on core innovations and strategic growth. This collaboration not only streamlines the drug development pipeline but also ensures compliance with regulatory standards, enhancing the overall efficiency and reducing time-to-market for breakthrough biologic therapies.

North American market for Biologics and Biosimilars CXO Services is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Biologics and Biosimilars CXO Services is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Biologics and Biosimilars CXO Services in API CXO is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Biologics and Biosimilars CXO Services include Catalent, Thermo Fisher Scientific, Lonza, Siegfried, Recipharm, Boehringer Ingelheim, WuXi AppTech, WuXi Biologics, Fareva, Samsung Biologics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Biologics and Biosimilars CXO Services, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologics and Biosimilars CXO Services.

The Biologics and Biosimilars CXO Services market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biologics and Biosimilars CXO Services market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Biologics and Biosimilars CXO Services companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Biologics and Biosimilars CXO Services Market Report

Report Metric	Details
Report Name	Biologics and Biosimilars CXO Services Market
Accounted market size in 2023	US$ 54540 million
Forecasted market size in 2030	US$ 96550 million
CAGR	8.5%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	CRO CDMO/CMO CSO
Segment by Application	API CXO FDF CXO Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Catalent, Thermo Fisher Scientific, Lonza, Siegfried, Recipharm, Boehringer Ingelheim, WuXi AppTech, WuXi Biologics, Fareva, Samsung Biologics, Aenova, Delpharm, Strides Pharma, Piramal, Famar, Curia, Jubilant, Vetter, AGC Pharma Chemicals, Asymchem, Pharmaron, Eurofins, Ascendia Pharmaceuticals, Ardena, CPL, UPM Pharmaceuticals, FUJIFILM Diosynth Biotechnologies, Groupe Parima, TBD Pharmatech, Avid Bioservices, NextPharma, Alcami, Societal CDMO, MedPharm, Euroapi, BioVectra, Pfizer CentreOne, Fermion
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biologics and Biosimilars CXO Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Biologics and Biosimilars CXO Services Market growing?

Ans: The Biologics and Biosimilars CXO Services Market witnessing a CAGR of 8.5% during the forecast period 2024-2030.

What is the Biologics and Biosimilars CXO Services Market size in 2030?

Ans: The Biologics and Biosimilars CXO Services Market size in 2030 will be US$ 96550 million.

Who are the main players in the Biologics and Biosimilars CXO Services Market report?

Ans: The main players in the Biologics and Biosimilars CXO Services Market are Catalent, Thermo Fisher Scientific, Lonza, Siegfried, Recipharm, Boehringer Ingelheim, WuXi AppTech, WuXi Biologics, Fareva, Samsung Biologics, Aenova, Delpharm, Strides Pharma, Piramal, Famar, Curia, Jubilant, Vetter, AGC Pharma Chemicals, Asymchem, Pharmaron, Eurofins, Ascendia Pharmaceuticals, Ardena, CPL, UPM Pharmaceuticals, FUJIFILM Diosynth Biotechnologies, Groupe Parima, TBD Pharmatech, Avid Bioservices, NextPharma, Alcami, Societal CDMO, MedPharm, Euroapi, BioVectra, Pfizer CentreOne, Fermion

What are the Application segmentation covered in the Biologics and Biosimilars CXO Services Market report?

Ans: The Applications covered in the Biologics and Biosimilars CXO Services Market report are API CXO, FDF CXO, Other

What are the Type segmentation covered in the Biologics and Biosimilars CXO Services Market report?

Ans: The Types covered in the Biologics and Biosimilars CXO Services Market report are CRO, CDMO/CMO, CSO

Recommended Reports

Biologics & Biosimilars Services

Biosimilar & Biologic Markets

Related Biopharma Segments

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Biologics and Biosimilars CXO Services Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 CRO

1.2.3 CDMO/CMO

1.2.4 CSO

1.3 Market by Application

1.3.1 Global Biologics and Biosimilars CXO Services Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 API CXO

1.3.3 FDF CXO

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Biologics and Biosimilars CXO Services Market Perspective (2019-2030)

2.2 Global Biologics and Biosimilars CXO Services Growth Trends by Region

2.2.1 Global Biologics and Biosimilars CXO Services Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Biologics and Biosimilars CXO Services Historic Market Size by Region (2019-2024)

2.2.3 Biologics and Biosimilars CXO Services Forecasted Market Size by Region (2025-2030)

2.3 Biologics and Biosimilars CXO Services Market Dynamics

2.3.1 Biologics and Biosimilars CXO Services Industry Trends

2.3.2 Biologics and Biosimilars CXO Services Market Drivers

2.3.3 Biologics and Biosimilars CXO Services Market Challenges

2.3.4 Biologics and Biosimilars CXO Services Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Biologics and Biosimilars CXO Services Players by Revenue

3.1.1 Global Top Biologics and Biosimilars CXO Services Players by Revenue (2019-2024)

3.1.2 Global Biologics and Biosimilars CXO Services Revenue Market Share by Players (2019-2024)

3.2 Global Biologics and Biosimilars CXO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Biologics and Biosimilars CXO Services Revenue

3.4 Global Biologics and Biosimilars CXO Services Market Concentration Ratio

3.4.1 Global Biologics and Biosimilars CXO Services Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Biologics and Biosimilars CXO Services Revenue in 2023

3.5 Global Key Players of Biologics and Biosimilars CXO Services Head office and Area Served

3.6 Global Key Players of Biologics and Biosimilars CXO Services, Product and Application

3.7 Global Key Players of Biologics and Biosimilars CXO Services, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Biologics and Biosimilars CXO Services Breakdown Data by Type

4.1 Global Biologics and Biosimilars CXO Services Historic Market Size by Type (2019-2024)

4.2 Global Biologics and Biosimilars CXO Services Forecasted Market Size by Type (2025-2030)

5 Biologics and Biosimilars CXO Services Breakdown Data by Application

5.1 Global Biologics and Biosimilars CXO Services Historic Market Size by Application (2019-2024)

5.2 Global Biologics and Biosimilars CXO Services Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Biologics and Biosimilars CXO Services Market Size (2019-2030)

6.2 North America Biologics and Biosimilars CXO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Biologics and Biosimilars CXO Services Market Size by Country (2019-2024)

6.4 North America Biologics and Biosimilars CXO Services Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Biologics and Biosimilars CXO Services Market Size (2019-2030)

7.2 Europe Biologics and Biosimilars CXO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Biologics and Biosimilars CXO Services Market Size by Country (2019-2024)

7.4 Europe Biologics and Biosimilars CXO Services Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Biologics and Biosimilars CXO Services Market Size (2019-2030)

8.2 Asia-Pacific Biologics and Biosimilars CXO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Biologics and Biosimilars CXO Services Market Size by Region (2019-2024)

8.4 Asia-Pacific Biologics and Biosimilars CXO Services Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Biologics and Biosimilars CXO Services Market Size (2019-2030)

9.2 Latin America Biologics and Biosimilars CXO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Biologics and Biosimilars CXO Services Market Size by Country (2019-2024)

9.4 Latin America Biologics and Biosimilars CXO Services Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Biologics and Biosimilars CXO Services Market Size (2019-2030)

10.2 Middle East & Africa Biologics and Biosimilars CXO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Biologics and Biosimilars CXO Services Market Size by Country (2019-2024)

10.4 Middle East & Africa Biologics and Biosimilars CXO Services Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Catalent

11.1.1 Catalent Company Details

11.1.2 Catalent Business Overview

11.1.3 Catalent Biologics and Biosimilars CXO Services Introduction

11.1.4 Catalent Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.1.5 Catalent Recent Development

11.2 Thermo Fisher Scientific

11.2.1 Thermo Fisher Scientific Company Details

11.2.2 Thermo Fisher Scientific Business Overview

11.2.3 Thermo Fisher Scientific Biologics and Biosimilars CXO Services Introduction

11.2.4 Thermo Fisher Scientific Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.2.5 Thermo Fisher Scientific Recent Development

11.3 Lonza

11.3.1 Lonza Company Details

11.3.2 Lonza Business Overview

11.3.3 Lonza Biologics and Biosimilars CXO Services Introduction

11.3.4 Lonza Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.3.5 Lonza Recent Development

11.4 Siegfried

11.4.1 Siegfried Company Details

11.4.2 Siegfried Business Overview

11.4.3 Siegfried Biologics and Biosimilars CXO Services Introduction

11.4.4 Siegfried Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.4.5 Siegfried Recent Development

11.5 Recipharm

11.5.1 Recipharm Company Details

11.5.2 Recipharm Business Overview

11.5.3 Recipharm Biologics and Biosimilars CXO Services Introduction

11.5.4 Recipharm Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.5.5 Recipharm Recent Development

11.6 Boehringer Ingelheim

11.6.1 Boehringer Ingelheim Company Details

11.6.2 Boehringer Ingelheim Business Overview

11.6.3 Boehringer Ingelheim Biologics and Biosimilars CXO Services Introduction

11.6.4 Boehringer Ingelheim Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.6.5 Boehringer Ingelheim Recent Development

11.7 WuXi AppTech

11.7.1 WuXi AppTech Company Details

11.7.2 WuXi AppTech Business Overview

11.7.3 WuXi AppTech Biologics and Biosimilars CXO Services Introduction

11.7.4 WuXi AppTech Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.7.5 WuXi AppTech Recent Development

11.8 WuXi Biologics

11.8.1 WuXi Biologics Company Details

11.8.2 WuXi Biologics Business Overview

11.8.3 WuXi Biologics Biologics and Biosimilars CXO Services Introduction

11.8.4 WuXi Biologics Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.8.5 WuXi Biologics Recent Development

11.9 Fareva

11.9.1 Fareva Company Details

11.9.2 Fareva Business Overview

11.9.3 Fareva Biologics and Biosimilars CXO Services Introduction

11.9.4 Fareva Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.9.5 Fareva Recent Development

11.10 Samsung Biologics

11.10.1 Samsung Biologics Company Details

11.10.2 Samsung Biologics Business Overview

11.10.3 Samsung Biologics Biologics and Biosimilars CXO Services Introduction

11.10.4 Samsung Biologics Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.10.5 Samsung Biologics Recent Development

11.11 Aenova

11.11.1 Aenova Company Details

11.11.2 Aenova Business Overview

11.11.3 Aenova Biologics and Biosimilars CXO Services Introduction

11.11.4 Aenova Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.11.5 Aenova Recent Development

11.12 Delpharm

11.12.1 Delpharm Company Details

11.12.2 Delpharm Business Overview

11.12.3 Delpharm Biologics and Biosimilars CXO Services Introduction

11.12.4 Delpharm Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.12.5 Delpharm Recent Development

11.13 Strides Pharma

11.13.1 Strides Pharma Company Details

11.13.2 Strides Pharma Business Overview

11.13.3 Strides Pharma Biologics and Biosimilars CXO Services Introduction

11.13.4 Strides Pharma Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.13.5 Strides Pharma Recent Development

11.14 Piramal

11.14.1 Piramal Company Details

11.14.2 Piramal Business Overview

11.14.3 Piramal Biologics and Biosimilars CXO Services Introduction

11.14.4 Piramal Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.14.5 Piramal Recent Development

11.15 Famar

11.15.1 Famar Company Details

11.15.2 Famar Business Overview

11.15.3 Famar Biologics and Biosimilars CXO Services Introduction

11.15.4 Famar Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.15.5 Famar Recent Development

11.16 Curia

11.16.1 Curia Company Details

11.16.2 Curia Business Overview

11.16.3 Curia Biologics and Biosimilars CXO Services Introduction

11.16.4 Curia Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.16.5 Curia Recent Development

11.17 Jubilant

11.17.1 Jubilant Company Details

11.17.2 Jubilant Business Overview

11.17.3 Jubilant Biologics and Biosimilars CXO Services Introduction

11.17.4 Jubilant Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.17.5 Jubilant Recent Development

11.18 Vetter

11.18.1 Vetter Company Details

11.18.2 Vetter Business Overview

11.18.3 Vetter Biologics and Biosimilars CXO Services Introduction

11.18.4 Vetter Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.18.5 Vetter Recent Development

11.19 AGC Pharma Chemicals

11.19.1 AGC Pharma Chemicals Company Details

11.19.2 AGC Pharma Chemicals Business Overview

11.19.3 AGC Pharma Chemicals Biologics and Biosimilars CXO Services Introduction

11.19.4 AGC Pharma Chemicals Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.19.5 AGC Pharma Chemicals Recent Development

11.20 Asymchem

11.20.1 Asymchem Company Details

11.20.2 Asymchem Business Overview

11.20.3 Asymchem Biologics and Biosimilars CXO Services Introduction

11.20.4 Asymchem Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.20.5 Asymchem Recent Development

11.21 Pharmaron

11.21.1 Pharmaron Company Details

11.21.2 Pharmaron Business Overview

11.21.3 Pharmaron Biologics and Biosimilars CXO Services Introduction

11.21.4 Pharmaron Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.21.5 Pharmaron Recent Development

11.22 Eurofins

11.22.1 Eurofins Company Details

11.22.2 Eurofins Business Overview

11.22.3 Eurofins Biologics and Biosimilars CXO Services Introduction

11.22.4 Eurofins Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.22.5 Eurofins Recent Development

11.23 Ascendia Pharmaceuticals

11.23.1 Ascendia Pharmaceuticals Company Details

11.23.2 Ascendia Pharmaceuticals Business Overview

11.23.3 Ascendia Pharmaceuticals Biologics and Biosimilars CXO Services Introduction

11.23.4 Ascendia Pharmaceuticals Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.23.5 Ascendia Pharmaceuticals Recent Development

11.24 Ardena

11.24.1 Ardena Company Details

11.24.2 Ardena Business Overview

11.24.3 Ardena Biologics and Biosimilars CXO Services Introduction

11.24.4 Ardena Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.24.5 Ardena Recent Development

11.25 CPL

11.25.1 CPL Company Details

11.25.2 CPL Business Overview

11.25.3 CPL Biologics and Biosimilars CXO Services Introduction

11.25.4 CPL Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.25.5 CPL Recent Development

11.26 UPM Pharmaceuticals

11.26.1 UPM Pharmaceuticals Company Details

11.26.2 UPM Pharmaceuticals Business Overview

11.26.3 UPM Pharmaceuticals Biologics and Biosimilars CXO Services Introduction

11.26.4 UPM Pharmaceuticals Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.26.5 UPM Pharmaceuticals Recent Development

11.27 FUJIFILM Diosynth Biotechnologies

11.27.1 FUJIFILM Diosynth Biotechnologies Company Details

11.27.2 FUJIFILM Diosynth Biotechnologies Business Overview

11.27.3 FUJIFILM Diosynth Biotechnologies Biologics and Biosimilars CXO Services Introduction

11.27.4 FUJIFILM Diosynth Biotechnologies Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.27.5 FUJIFILM Diosynth Biotechnologies Recent Development

11.28 Groupe Parima

11.28.1 Groupe Parima Company Details

11.28.2 Groupe Parima Business Overview

11.28.3 Groupe Parima Biologics and Biosimilars CXO Services Introduction

11.28.4 Groupe Parima Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.28.5 Groupe Parima Recent Development

11.29 TBD Pharmatech

11.29.1 TBD Pharmatech Company Details

11.29.2 TBD Pharmatech Business Overview

11.29.3 TBD Pharmatech Biologics and Biosimilars CXO Services Introduction

11.29.4 TBD Pharmatech Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.29.5 TBD Pharmatech Recent Development

11.30 Avid Bioservices

11.30.1 Avid Bioservices Company Details

11.30.2 Avid Bioservices Business Overview

11.30.3 Avid Bioservices Biologics and Biosimilars CXO Services Introduction

11.30.4 Avid Bioservices Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.30.5 Avid Bioservices Recent Development

11.31 NextPharma

11.31.1 NextPharma Company Details

11.31.2 NextPharma Business Overview

11.31.3 NextPharma Biologics and Biosimilars CXO Services Introduction

11.31.4 NextPharma Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.31.5 NextPharma Recent Development

11.32 Alcami

11.32.1 Alcami Company Details

11.32.2 Alcami Business Overview

11.32.3 Alcami Biologics and Biosimilars CXO Services Introduction

11.32.4 Alcami Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.32.5 Alcami Recent Development

11.33 Societal CDMO

11.33.1 Societal CDMO Company Details

11.33.2 Societal CDMO Business Overview

11.33.3 Societal CDMO Biologics and Biosimilars CXO Services Introduction

11.33.4 Societal CDMO Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.33.5 Societal CDMO Recent Development

11.34 MedPharm

11.34.1 MedPharm Company Details

11.34.2 MedPharm Business Overview

11.34.3 MedPharm Biologics and Biosimilars CXO Services Introduction

11.34.4 MedPharm Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.34.5 MedPharm Recent Development

11.35 Euroapi

11.35.1 Euroapi Company Details

11.35.2 Euroapi Business Overview

11.35.3 Euroapi Biologics and Biosimilars CXO Services Introduction

11.35.4 Euroapi Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.35.5 Euroapi Recent Development

11.36 BioVectra

11.36.1 BioVectra Company Details

11.36.2 BioVectra Business Overview

11.36.3 BioVectra Biologics and Biosimilars CXO Services Introduction

11.36.4 BioVectra Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.36.5 BioVectra Recent Development

11.37 Pfizer CentreOne

11.37.1 Pfizer CentreOne Company Details

11.37.2 Pfizer CentreOne Business Overview

11.37.3 Pfizer CentreOne Biologics and Biosimilars CXO Services Introduction

11.37.4 Pfizer CentreOne Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.37.5 Pfizer CentreOne Recent Development

11.38 Fermion

11.38.1 Fermion Company Details

11.38.2 Fermion Business Overview

11.38.3 Fermion Biologics and Biosimilars CXO Services Introduction

11.38.4 Fermion Revenue in Biologics and Biosimilars CXO Services Business (2019-2024)

11.38.5 Fermion Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Companies

Catalent

Thermo Fisher Scientific

Lonza

Siegfried

Recipharm

Boehringer Ingelheim

WuXi AppTech

Wuxi Biologics

Fareva

Samsung Biologics

Aenova

Delpharm

Strides Pharma

Piramal

Famar

Curia

Jubilant

Vetter

AGC Pharma Chemicals

Asymchem

Pharmaron

Eurofins

Ascendia Pharmaceuticals

Ardena

CPL

UPM Pharmaceuticals

FUJIFILM Diosynth Biotechnologies

Groupe Parima

TBD Pharmatech

Avid Bioservices

NextPharma

Alcami

Societal CDMO

MedPharm Ltd.

EUROAPI

BioVectra

Pfizer CentreOne

Fermion

List of Tables

Table 1. Global Biologics and Biosimilars CXO Services Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of CRO

Table 3. Key Players of CDMO/CMO

Table 4. Key Players of CSO

Table 5. Global Biologics and Biosimilars CXO Services Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Biologics and Biosimilars CXO Services Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Biologics and Biosimilars CXO Services Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global Biologics and Biosimilars CXO Services Market Share by Region (2019-2024)

Table 9. Global Biologics and Biosimilars CXO Services Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global Biologics and Biosimilars CXO Services Market Share by Region (2025-2030)

Table 11. Biologics and Biosimilars CXO Services Market Trends

Table 12. Biologics and Biosimilars CXO Services Market Drivers

Table 13. Biologics and Biosimilars CXO Services Market Challenges

Table 14. Biologics and Biosimilars CXO Services Market Restraints

Table 15. Global Biologics and Biosimilars CXO Services Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global Biologics and Biosimilars CXO Services Market Share by Players (2019-2024)

Table 17. Global Top Biologics and Biosimilars CXO Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biologics and Biosimilars CXO Services as of 2023)

Table 18. Ranking of Global Top Biologics and Biosimilars CXO Services Companies by Revenue (US$ Million) in 2023

Table 19. Global 5 Largest Players Market Share by Biologics and Biosimilars CXO Services Revenue (CR5 and HHI) & (2019-2024)

Table 20. Global Key Players of Biologics and Biosimilars CXO Services, Headquarters and Area Served

Table 21. Global Key Players of Biologics and Biosimilars CXO Services, Product and Application

Table 22. Global Key Players of Biologics and Biosimilars CXO Services, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Biologics and Biosimilars CXO Services Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global Biologics and Biosimilars CXO Services Revenue Market Share by Type (2019-2024)

Table 26. Global Biologics and Biosimilars CXO Services Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global Biologics and Biosimilars CXO Services Revenue Market Share by Type (2025-2030)

Table 28. Global Biologics and Biosimilars CXO Services Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global Biologics and Biosimilars CXO Services Revenue Market Share by Application (2019-2024)

Table 30. Global Biologics and Biosimilars CXO Services Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global Biologics and Biosimilars CXO Services Revenue Market Share by Application (2025-2030)

Table 32. North America Biologics and Biosimilars CXO Services Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 33. North America Biologics and Biosimilars CXO Services Market Size by Country (2019-2024) & (US$ Million)

Table 34. North America Biologics and Biosimilars CXO Services Market Size by Country (2025-2030) & (US$ Million)

Table 35. Europe Biologics and Biosimilars CXO Services Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. Europe Biologics and Biosimilars CXO Services Market Size by Country (2019-2024) & (US$ Million)

Table 37. Europe Biologics and Biosimilars CXO Services Market Size by Country (2025-2030) & (US$ Million)

Table 38. Asia-Pacific Biologics and Biosimilars CXO Services Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 39. Asia-Pacific Biologics and Biosimilars CXO Services Market Size by Region (2019-2024) & (US$ Million)

Table 40. Asia-Pacific Biologics and Biosimilars CXO Services Market Size by Region (2025-2030) & (US$ Million)

Table 41. Latin America Biologics and Biosimilars CXO Services Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 42. Latin America Biologics and Biosimilars CXO Services Market Size by Country (2019-2024) & (US$ Million)

Table 43. Latin America Biologics and Biosimilars CXO Services Market Size by Country (2025-2030) & (US$ Million)

Table 44. Middle East & Africa Biologics and Biosimilars CXO Services Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Middle East & Africa Biologics and Biosimilars CXO Services Market Size by Country (2019-2024) & (US$ Million)

Table 46. Middle East & Africa Biologics and Biosimilars CXO Services Market Size by Country (2025-2030) & (US$ Million)

Table 47. Catalent Company Details

Table 48. Catalent Business Overview

Table 49. Catalent Biologics and Biosimilars CXO Services Product

Table 50. Catalent Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 51. Catalent Recent Development

Table 52. Thermo Fisher Scientific Company Details

Table 53. Thermo Fisher Scientific Business Overview

Table 54. Thermo Fisher Scientific Biologics and Biosimilars CXO Services Product

Table 55. Thermo Fisher Scientific Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 56. Thermo Fisher Scientific Recent Development

Table 57. Lonza Company Details

Table 58. Lonza Business Overview

Table 59. Lonza Biologics and Biosimilars CXO Services Product

Table 60. Lonza Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 61. Lonza Recent Development

Table 62. Siegfried Company Details

Table 63. Siegfried Business Overview

Table 64. Siegfried Biologics and Biosimilars CXO Services Product

Table 65. Siegfried Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 66. Siegfried Recent Development

Table 67. Recipharm Company Details

Table 68. Recipharm Business Overview

Table 69. Recipharm Biologics and Biosimilars CXO Services Product

Table 70. Recipharm Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 71. Recipharm Recent Development

Table 72. Boehringer Ingelheim Company Details

Table 73. Boehringer Ingelheim Business Overview

Table 74. Boehringer Ingelheim Biologics and Biosimilars CXO Services Product

Table 75. Boehringer Ingelheim Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 76. Boehringer Ingelheim Recent Development

Table 77. WuXi AppTech Company Details

Table 78. WuXi AppTech Business Overview

Table 79. WuXi AppTech Biologics and Biosimilars CXO Services Product

Table 80. WuXi AppTech Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 81. WuXi AppTech Recent Development

Table 82. WuXi Biologics Company Details

Table 83. WuXi Biologics Business Overview

Table 84. WuXi Biologics Biologics and Biosimilars CXO Services Product

Table 85. WuXi Biologics Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 86. WuXi Biologics Recent Development

Table 87. Fareva Company Details

Table 88. Fareva Business Overview

Table 89. Fareva Biologics and Biosimilars CXO Services Product

Table 90. Fareva Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 91. Fareva Recent Development

Table 92. Samsung Biologics Company Details

Table 93. Samsung Biologics Business Overview

Table 94. Samsung Biologics Biologics and Biosimilars CXO Services Product

Table 95. Samsung Biologics Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 96. Samsung Biologics Recent Development

Table 97. Aenova Company Details

Table 98. Aenova Business Overview

Table 99. Aenova Biologics and Biosimilars CXO Services Product

Table 100. Aenova Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 101. Aenova Recent Development

Table 102. Delpharm Company Details

Table 103. Delpharm Business Overview

Table 104. Delpharm Biologics and Biosimilars CXO Services Product

Table 105. Delpharm Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 106. Delpharm Recent Development

Table 107. Strides Pharma Company Details

Table 108. Strides Pharma Business Overview

Table 109. Strides Pharma Biologics and Biosimilars CXO Services Product

Table 110. Strides Pharma Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 111. Strides Pharma Recent Development

Table 112. Piramal Company Details

Table 113. Piramal Business Overview

Table 114. Piramal Biologics and Biosimilars CXO Services Product

Table 115. Piramal Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 116. Piramal Recent Development

Table 117. Famar Company Details

Table 118. Famar Business Overview

Table 119. Famar Biologics and Biosimilars CXO Services Product

Table 120. Famar Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 121. Famar Recent Development

Table 122. Curia Company Details

Table 123. Curia Business Overview

Table 124. Curia Biologics and Biosimilars CXO Services Product

Table 125. Curia Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 126. Curia Recent Development

Table 127. Jubilant Company Details

Table 128. Jubilant Business Overview

Table 129. Jubilant Biologics and Biosimilars CXO Services Product

Table 130. Jubilant Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 131. Jubilant Recent Development

Table 132. Vetter Company Details

Table 133. Vetter Business Overview

Table 134. Vetter Biologics and Biosimilars CXO Services Product

Table 135. Vetter Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 136. Vetter Recent Development

Table 137. AGC Pharma Chemicals Company Details

Table 138. AGC Pharma Chemicals Business Overview

Table 139. AGC Pharma Chemicals Biologics and Biosimilars CXO Services Product

Table 140. AGC Pharma Chemicals Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 141. AGC Pharma Chemicals Recent Development

Table 142. Asymchem Company Details

Table 143. Asymchem Business Overview

Table 144. Asymchem Biologics and Biosimilars CXO Services Product

Table 145. Asymchem Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 146. Asymchem Recent Development

Table 147. Pharmaron Company Details

Table 148. Pharmaron Business Overview

Table 149. Pharmaron Biologics and Biosimilars CXO Services Product

Table 150. Pharmaron Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 151. Pharmaron Recent Development

Table 152. Eurofins Company Details

Table 153. Eurofins Business Overview

Table 154. Eurofins Biologics and Biosimilars CXO Services Product

Table 155. Eurofins Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 156. Eurofins Recent Development

Table 157. Ascendia Pharmaceuticals Company Details

Table 158. Ascendia Pharmaceuticals Business Overview

Table 159. Ascendia Pharmaceuticals Biologics and Biosimilars CXO Services Product

Table 160. Ascendia Pharmaceuticals Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 161. Ascendia Pharmaceuticals Recent Development

Table 162. Ardena Company Details

Table 163. Ardena Business Overview

Table 164. Ardena Biologics and Biosimilars CXO Services Product

Table 165. Ardena Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 166. Ardena Recent Development

Table 167. CPL Company Details

Table 168. CPL Business Overview

Table 169. CPL Biologics and Biosimilars CXO Services Product

Table 170. CPL Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 171. CPL Recent Development

Table 172. UPM Pharmaceuticals Company Details

Table 173. UPM Pharmaceuticals Business Overview

Table 174. UPM Pharmaceuticals Biologics and Biosimilars CXO Services Product

Table 175. UPM Pharmaceuticals Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 176. UPM Pharmaceuticals Recent Development

Table 177. FUJIFILM Diosynth Biotechnologies Company Details

Table 178. FUJIFILM Diosynth Biotechnologies Business Overview

Table 179. FUJIFILM Diosynth Biotechnologies Biologics and Biosimilars CXO Services Product

Table 180. FUJIFILM Diosynth Biotechnologies Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 181. FUJIFILM Diosynth Biotechnologies Recent Development

Table 182. Groupe Parima Company Details

Table 183. Groupe Parima Business Overview

Table 184. Groupe Parima Biologics and Biosimilars CXO Services Product

Table 185. Groupe Parima Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 186. Groupe Parima Recent Development

Table 187. TBD Pharmatech Company Details

Table 188. TBD Pharmatech Business Overview

Table 189. TBD Pharmatech Biologics and Biosimilars CXO Services Product

Table 190. TBD Pharmatech Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 191. TBD Pharmatech Recent Development

Table 192. Avid Bioservices Company Details

Table 193. Avid Bioservices Business Overview

Table 194. Avid Bioservices Biologics and Biosimilars CXO Services Product

Table 195. Avid Bioservices Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 196. Avid Bioservices Recent Development

Table 197. NextPharma Company Details

Table 198. NextPharma Business Overview

Table 199. NextPharma Biologics and Biosimilars CXO Services Product

Table 200. NextPharma Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 201. NextPharma Recent Development

Table 202. Alcami Company Details

Table 203. Alcami Business Overview

Table 204. Alcami Biologics and Biosimilars CXO Services Product

Table 205. Alcami Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 206. Alcami Recent Development

Table 207. Societal CDMO Company Details

Table 208. Societal CDMO Business Overview

Table 209. Societal CDMO Biologics and Biosimilars CXO Services Product

Table 210. Societal CDMO Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 211. Societal CDMO Recent Development

Table 212. MedPharm Company Details

Table 213. MedPharm Business Overview

Table 214. MedPharm Biologics and Biosimilars CXO Services Product

Table 215. MedPharm Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 216. MedPharm Recent Development

Table 217. Euroapi Company Details

Table 218. Euroapi Business Overview

Table 219. Euroapi Biologics and Biosimilars CXO Services Product

Table 220. Euroapi Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 221. Euroapi Recent Development

Table 222. BioVectra Company Details

Table 223. BioVectra Business Overview

Table 224. BioVectra Biologics and Biosimilars CXO Services Product

Table 225. BioVectra Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 226. BioVectra Recent Development

Table 227. Pfizer CentreOne Company Details

Table 228. Pfizer CentreOne Business Overview

Table 229. Pfizer CentreOne Biologics and Biosimilars CXO Services Product

Table 230. Pfizer CentreOne Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 231. Pfizer CentreOne Recent Development

Table 232. Fermion Company Details

Table 233. Fermion Business Overview

Table 234. Fermion Biologics and Biosimilars CXO Services Product

Table 235. Fermion Revenue in Biologics and Biosimilars CXO Services Business (2019-2024) & (US$ Million)

Table 236. Fermion Recent Development

Table 237. Research Programs/Design for This Report

Table 238. Key Data Information from Secondary Sources

Table 239. Key Data Information from Primary Sources

Table 240. Authors List of This Report

List of Figures

Figure 1. Biologics and Biosimilars CXO Services Picture

Figure 2. Global Biologics and Biosimilars CXO Services Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Biologics and Biosimilars CXO Services Market Share by Type: 2023 VS 2030

Figure 4. CRO Features

Figure 5. CDMO/CMO Features

Figure 6. CSO Features

Figure 7. Global Biologics and Biosimilars CXO Services Market Size by Application (2024-2030) & (US$ Million)

Figure 8. Global Biologics and Biosimilars CXO Services Market Share by Application: 2023 VS 2030

Figure 9. API CXO Case Studies

Figure 10. FDF CXO Case Studies

Figure 11. Other Case Studies

Figure 12. Biologics and Biosimilars CXO Services Report Years Considered

Figure 13. Global Biologics and Biosimilars CXO Services Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 14. Global Biologics and Biosimilars CXO Services Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 15. Global Biologics and Biosimilars CXO Services Market Share by Region: 2023 VS 2030

Figure 16. Global Biologics and Biosimilars CXO Services Market Share by Players in 2023

Figure 17. Global Top Biologics and Biosimilars CXO Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biologics and Biosimilars CXO Services as of 2023)

Figure 18. The Top 10 and 5 Players Market Share by Biologics and Biosimilars CXO Services Revenue in 2023

Figure 19. North America Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. North America Biologics and Biosimilars CXO Services Market Share by Country (2019-2030)

Figure 21. United States Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Canada Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe Biologics and Biosimilars CXO Services Market Share by Country (2019-2030)

Figure 25. Germany Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. France Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. U.K. Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Italy Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Russia Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Nordic Countries Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Asia-Pacific Biologics and Biosimilars CXO Services Market Share by Region (2019-2030)

Figure 33. China Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Japan Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. South Korea Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Southeast Asia Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. India Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Australia Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Latin America Biologics and Biosimilars CXO Services Market Share by Country (2019-2030)

Figure 41. Mexico Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Brazil Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Middle East & Africa Biologics and Biosimilars CXO Services Market Share by Country (2019-2030)

Figure 45. Turkey Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Saudi Arabia Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. UAE Biologics and Biosimilars CXO Services Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Catalent Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 49. Thermo Fisher Scientific Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 50. Lonza Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 51. Siegfried Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 52. Recipharm Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 53. Boehringer Ingelheim Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 54. WuXi AppTech Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 55. WuXi Biologics Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 56. Fareva Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 57. Samsung Biologics Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 58. Aenova Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 59. Delpharm Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 60. Strides Pharma Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 61. Piramal Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 62. Famar Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 63. Curia Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 64. Jubilant Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 65. Vetter Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 66. AGC Pharma Chemicals Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 67. Asymchem Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 68. Pharmaron Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 69. Eurofins Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 70. Ascendia Pharmaceuticals Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 71. Ardena Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 72. CPL Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 73. UPM Pharmaceuticals Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 74. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 75. Groupe Parima Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 76. TBD Pharmatech Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 77. Avid Bioservices Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 78. NextPharma Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 79. Alcami Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 80. Societal CDMO Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 81. MedPharm Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 82. Euroapi Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 83. BioVectra Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 84. Pfizer CentreOne Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 85. Fermion Revenue Growth Rate in Biologics and Biosimilars CXO Services Business (2019-2024)

Figure 86. Bottom-up and Top-down Approaches for This Report

Figure 87. Data Triangulation

Figure 88. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Biopharmaceutical CXO Market Research Report 2024

Global Medical CXO Services Market Research Report 2024

Global Biologics Analytical Services Market Research Report 2024

Global Biologics Outsourcing Services Market Research Report 2024

Biopharmaceutical CMO CRO Market

Pharmaceutical CXO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Biotechnology Contract Manufacturing Market Research Report 2024

Global Chemical Drug CXO Services Market Research Report 2024

Biopharmaceutical Development Support Service Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Innovations in Biologics and Biosimilars Market Research Report 2024

Global Biopharmaceutical Process Development Services Market Research Report 2025

Global Biologics and Biosimilars Market Research Report 2025

Biopharmaceutical Testing Services Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Biopharmaceuticals Contract Manufacturing Service Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Outsourcing Drug Discovery Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Biologics Drug Discovery and Development Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

New Drug Research and Development Services Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-14Y6812

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-34O3983

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9V17601

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22C17047

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions